BiotechTube
Celltheon

Celltheon

Cambridge, United States· Est.
celltheon.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $18M

Overview

Celltheon is a private, platform-and-services biotech firm founded in 2018, specializing in advanced protein expression and cell line development. Its core offering is the CELLTHEON SMART™ platform, a suite of technologies including the OmniCHO™ transient system, engineered cell lines, and vector systems designed to achieve high titers and consistent product quality. The company operates as a service provider and technology licensor, supporting biopharma partners in overcoming manufacturing hurdles for complex biologics, positioning it in the critical enabler space of the therapeutics industry. It appears to be in an early-revenue stage, serving the preclinical development needs of its clients.

Oncology

Technology Platform

CELLTHEON SMART™ Expression Platform, featuring OmniCHO™ (high-titer CHO-K1 transient expression), pCT™ Vectors, SUPERCELL™ (engineered CHO cells), GOLDILOCKS TRANSPOSASE™, CHROMASelect™ (high-throughput clone screening), and SMART BIOPROCESSING™ solutions.

Funding History

2
Total raised:$18M
Series A$15M
Seed$3M

Opportunities

The growing pipeline of complex, difficult-to-express biologics (bispecifics, fusion proteins) creates strong demand for specialized development expertise.
Celltheon's high-titer transient and stable expression technologies can significantly accelerate preclinical timelines for clients, offering a compelling value proposition.
There is also an opportunity to license its proprietary platform components (e.g., OmniCHO kit, engineered cell lines) to other CDMOs or biotechs.

Risk Factors

Intense competition from large, established CDMOs and other technology-focused specialists poses a significant market penetration risk.
The company's success is heavily reliant on a small number of proprietary technologies; failure to perform consistently across diverse client molecules could harm its reputation.
As a service business dependent on biotech funding cycles, it is vulnerable to macroeconomic downturns that reduce R&D spending.

Competitive Landscape

Celltheon competes in the crowded biologics CDMO and cell line development technology space. Direct competitors include other specialist firms like Atum, Proteovista, and Selexis, as well as the in-house capabilities of large biopharma and the service arms of giants like Lonza and Thermo Fisher Scientific. Its differentiation hinges on the claimed superior titer and quality of its OmniCHO system and its integrated platform for tackling the most challenging protein formats.

More companies in Cell & Gene Therapy →More companies in United States →